Acute renoprotective effects of dapagliflozin monotherapy on albuminuria and metabolic derangements in newly diagnosed type 2 diabetes mellitus: a quasi-experimental study

Puntos clave

• Dapagliflozin significantly reduces albuminuria levels in newly diagnosed type 2 diabetes patients, indicating renal protective effects.
• The study reports a notable improvement in metabolic parameters associated with dapagliflozin treatment, with clear benefits observed.
• Quasi-experimental analysis shows substantial changes in renal function markers, marking the intervention's effectiveness in managing diabetes-related complications.
• These findings suggest the need for further research into dapagliflozin's long-term effects on renal health in diverse diabetic populations.